Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Digital Health Reimbursement Lobbying

Exec Chat: New CEO Of Digital Therapeutics Alliance Says Reimbursement Remains Big Issue

  • Interviews

Executive Summary

In an interview with Medtech Insight, Andy Molnar, new CEO of the Digital Therapeutics Alliance, outlines some of the big issues facing the digital therapeutics industry, which has seen tremendous growth during the pandemic.

You may also be interested in...



Kaiku Health To Build On 2020 Success With Rapid Expansion

With digital therapies and devices seeing widespread adoption in response to lockdown limitations during the COVID-19 pandemic, Kaiku Health is in a strong position to expand its patient monitoring software. CEO Lauri Sippola spoke with In Vivo about the platform and the company’s plans for 2021 and beyond.

Digital Health Roundup, July 2021: Exec Chat With DTA, Start-Ups Grab New Funds, Agency Nods

In this roundup feature focusing on the developments in digital health, we highlight the key news and announcements from July.

Mahana Therapeutics Plans To Use $61M In Series B Financing To Launch IBS Treatment App

Mahana is planning a 2022 nationwide launch of its FDA-cleared prescription digital therapeutic for treating symptoms of irritable bowel syndrome.

Table

View full table

Related Content

Medtech Insight
Medtech Insight

Topics

Related Companies

Tags:
Digital Health Reimbursement Lobbying
UsernamePublicRestriction

Register

MT144274

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By